All In Biotech

Drug Trial Radar · NCT01514500

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Dec 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jan 16, 2012

Primary completion

Mar 18, 2013

Study completion Mar 18, 2013

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 23, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 20 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of NNC0195-0092 (somapacitan) compared to placebo in healthy male subjects.

Conditions

  • Growth Hormone Disorder
  • Adult Growth Hormone Deficiency
  • Growth Hormone Deficiency in Children
  • Healthy

Interventions

  • somapacitanDrug

    Administered s.c. (subcutaneously, under the skin)

  • placebo (somapacitan)Drug

    Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (Single Dose)Time frame: From first administration of trial product and up until day 40
  2. Incidence of adverse events (Multiple Dose)Time frame: From first administration of trial product and up until day 49

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Neuss, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.